Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
CagriSema CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, co-administered once weekly and studied in Phase 3 trials for obesity and type 2 diabetes.
Common, mild side effects: Pain, redness, or itching at the injection site Mild nausea or diarrhea Headache Temporary dizziness Rare but more serious reactions: Allergic reactions (rash, swelling, breathing difficulty) Heart palpitations Low potassium levels during rapid correction of severe deficiency Very rare cases of anaphylaxis requiring emergency care Seek medical attention immediately if you experience symptoms of a serious allergic reaction
~5-fold potency at
Neither the legally suspect nor the legal option came close to the level of medical care I receive from my primary care provider, but the difference between the two was stark
US$ 27.63
US$ 23.02
US$ 25.83
US$ 20.40